Ricerca avanzata

Home > Riviste > International Angiology > Fascicoli precedenti > International Angiology 2016 Dicembre;35(6) > International Angiology 2016 Dicembre;35(6);534-45

FASCICOLI E ARTICOLI   I PIÙ LETTI   eTOC

ULTIMO FASCICOLOINTERNATIONAL ANGIOLOGY

Rivista di Angiologia

Official Journal of the International Union of Angiology, the International Union of Phlebology and the Central European Vascular Forum
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,899

Periodicità: Bimestrale

ISSN 0392-9590

Online ISSN 1827-1839

 

International Angiology 2016 Dicembre;35(6);534-45

 REVIEWS

A meta-analysis of adjusted observational studies and randomized controlled trials of endovascular versus open surgical repair for ruptured abdominal aortic aneurysm

Hisato TAKAGI, Takuya UMEMOTO, on behalf of the ALICE (All-Literature Investigation of Cardiovascular Evidence) Group

Department of Cardiovascular Surgery, Shizuoka Medical Center, Shizuoka, Japan

INTRODUCTION: The aim of the present meta-analysis was to determine whether endovascular aneurysm repair (EVAR) reduces perioperative mortality and improves overall survival compared with open surgical repair (OSR) in patients with ruptured abdominal aortic aneurysm (RAAA).
EVIDENCE ACQUISITION: Eligible studies were observational studies with adjusted risk estimates or randomized controlled trials (RCTs) of EVAR versus OSR enrolling individuals with RAAA and reporting perioperative (30-day or in-hospital) or overall (≥3-month) all-cause mortality.
EVIDENCE SYNTHESIS: Twenty-four adjusted observational studies and 4 RCTs enrolling a total of 56,826 patients with RAAA were identified and included. For perioperative all-cause mortality, pooled analyses of 22 adjusted observational studies and 4 RCTs respectively demonstrated a statistically significant 49% reduction with EVAR relative to OSR (odds ratio [OR]=0.51; 95% confidence interval [CI]: 0.44 to 0.59; P<0.00001) and no statistically significant difference between EVAR and OSR (OR=0.91; 95% CI: 0.68 to 1.22; P=0.53) (P for subgroup differences = 0.0006). For overall (3 months to 8 years) all-cause mortality, a pooled analysis of 7 adjusted observational studies (hazard ratio [HR]=0.92; 95% CI: 0.77 to 1.10; P=0.37) and 3 RCTs (HR=0.89; 95% CI: 0.69 to 1.14; P=0.34) demonstrated no statistically significant difference between EVAR and OSR (P for subgroup differences = 0.81).
CONCLUSIONS: In patients with RAAA, EVAR is likely effective in prevention of perioperative overall (3 months to 8 years), not all-cause mortality.

lingua: Inglese


FULL TEXT  ESTRATTI

inizio pagina